Latest Outlook Therapeutics News & Updates

See the latest news and media coverage for Outlook Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Outlook Therapeutics

Biopharmaceutical company developing ophthalmic therapies for retinal diseases

outlooktherapeutics.com

Headquarters: Iselin, United States
Founded year: 2011
Company type: Public company
Number of employees: 10–80
Industry: Pharmaceuticals

Last updated Today

Latest news about Outlook Therapeutics

In short: Outlook Therapeutics received FDA approval for LYTENAVA to treat wet AMD and projected over $500 million in annual sales by 2030.

Company announcements

August 14 Outlook Therapeutics

Outlook Therapeutics reports quarterly results and FDA approval

It highlights LYTENAVA™’s FDA approval and schedules a corporate update conference call at 8:30 AM ET.

August 14 Outlook Therapeutics

Outlook Therapeutics reports Q3 FY2026 results and LYTENAVA approval

The only FDA-approved ophthalmic bevacizumab for wet AMD, LYTENAVA launch planned by end of 2026, with potential U.S. sales exceeding $500 million annually by 2030.

August 12 Outlook Therapeutics

Outlook Therapeutics announces proposed public offering of common stock and warrants

The biopharmaceutical company plans to use proceeds for LYTENAVA's U.S. commercial launch and general corporate purposes, with Piper Sandler and BTIG as joint bookrunners.

August 4 Outlook Therapeutics

Outlook Therapeutics shifts focus to delivering FDA-approved LYTENAVA

The FDA approval covers LYTENAVA (bevacizumab-vikg) injection for wet age-related macular degeneration, and the company is preparing its launch to retina specialists and patients.

Media coverage

August 18 The Globe and Mail

Outlook Therapeutics delays quarterly SEC filing

Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.

August 14 Seeking Alpha

Outlook Therapeutics targets more than $500M peak annual LYTENAVA sales by 2030 as it forecasts $50M-$75M first-year net revenue (NASDAQ:OTLK)

Outlook Therapeutics Q3 2026 earnings call: LYTENAVA FDA approval, launch plan, revenue guidance,...

August 13 Yahoo Finance

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%,...

August 13 Seeking Alpha

Here are the major earnings before the open Friday

Sigma Lithium, Digi Power X, Outlook Therapeutics, Lifeward, and RLX Technology are among the companies reporting earnings before Friday's open.

Never miss news about Outlook Therapeutics

Track Outlook Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Outlook Therapeutics competitors & trending companies

Browse news for competitors to Outlook Therapeutics and other trending companies.